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Abstract
Pandoraea are considered emerging multidrug resistant pathogens
in the context of cystic ﬁbrosis. We report herein for the ﬁrst
time the case of a 30-year-old woman with cystic ﬁbrosis, living in
France, who was chronically infected with Pandoraea pulmonicola
and who died of Pseudomonas aeruginosa sepsis 3 weeks after
bilateral lung transplantation.
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Introduction
Pandoraea species are non-fermentative, Gram-negative bac-
teria that are considered emerging multi-drug resistant
pathogens in the context of cystic ﬁbrosis (CF) [1]. The
genus Pandoraea was created in 2000 and now comprises at
least ﬁve validated species, i.e. Pandoraea apista, P. norimberg-
ensis, P. pnomenusa, P. pulmonicola and P. sputorum [1] (Fig. 1).
Conventional phenotypic laboratory methods remain prob-
lematic for the accurate identiﬁcation of these bacteria at the
species level and misidentiﬁcation with bacteria of the genus
Burkholderia and Ralstonia has been reported [2]. Although
these bacteria are emerging pathogens in CF patients, there
are very few clinical data on the clinical course and outcomes
for patients colonized with these bacteria especially in the
context of lung transplantation [2]. We report herein for the
ﬁrst time the case of a 30-year-old woman with CF, living in
France, who was chronically co-infected with P. pulmonicola
and Pseudomonas aeruginosa and who died of P. aeruginosa
sepsis 3 weeks after bilateral lung transplantation (BLT).
Case Report
A 30-year-old woman who was diagnosed with CF at
3 months of age with a homozygous ΔF508 mutation had
been infected with P. pulmonicola at least since October
2009. She was also chronically infected with P. aeruginosa
and was placed on the active waiting list for BLT from
January 2009. From October 2008 to March 2010, the
patient had a dramatic deterioration of her pulmonary
functional tests with a chronically persistent septic status
and intermittent fever. During this period, apart from P.
aeruginosa (resistant to all antibiotics except colistin), a
colistin-resistant Gram-negative bacterium was isolated
seven times from Cepacia agar. P. pulmonicola was eventually
identiﬁed by routine analysis by matrix assisted laser
desorption ionization–time of ﬂight mass spectrometry
(MALDI-TOF) [3] and conﬁrmed with 16S rDNA gene
sequence analysis (99.9% of similarity with GenBank acces-
sion number AF139175) (Strain 9405935, Fig. 1). The
susceptibility proﬁle of this organism demonstrated that
the organism was initially susceptible only to tigecycline and
rifampin, and resistant to ticarcillin, ticarcillin/clavulanic acid,
tazocillin, ceftazidime, imipenem, gentamycin, tobramycin,
fosfomycin, rifampin, trimethoprim/sulfamethoxazole, colistin,
ciproﬂoxacin and cefpirome.
In March 2010 the patient was admitted to the adult CF
reference centre in Marseille for persistent haemoptysis and
worsening of pulmonary infection. On examination she had
fever (38°C), and had lost 4 kg in weight during the previous
6 months. She presented stage III NYHA dyspnoea, cough and
purulent expectoration. Axial lung computed tomography
(CT) scan showed a large parenchymal cavity that occupied
almost all the right upper lobe, with a thick lobulated wall
(maximum thickness 7.5 mm) interpreted as an infarct pneu-
monia (Fig. 2A). Relevant laboratory ﬁndings included a white
blood cell count of 17, 78 G/L, a platelet count of 405 G/L,
C-reactive protein at 36 mg/L, and ﬁbrinogen at 4.8 g/L. She
had a new procedure of therapeutic bronchial artery embo-
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lization and an intravenous antibiotherapy with tigecycline
50 mg 9 2/day, colistin 2M 9 3/day, meropenem 2 g 9 3/
day and tobramycin 450 mg/day was started. The patient
received continuous oxygen therapy and intermittent
non-invasive ventilation but there was poor progress after
14 days with such therapy. The patient ﬁnally underwent BLT
3 weeks after her admission. Her condition worsened 5 days
after lung transplantation and P. aeruginosa was isolated from
blood cultures, lymph nodes, bronchoalveolar lavage, liquid
drains and pleural liquid whereas P. pulmonicola was cultured
only from one bronchoalveolar lavage on postoperative day
19. A CT scan of the lung showed diffuse bilateral alveolar
opacities and a parenchymal cavity 40 mm in diameter in the
left upper lobe (Fig. 2B). The patient died 3 weeks after the
BLT from multi-organ failure in septic shock despite intrave-
nous antibiotherapy.
Conclusions
During the last decade, many new and/or emerging multidrug
resistant pathogens (especially bacteria resistant to colistin)
have been described in CF patients including Burkholderia
cepacia complex, Inquilinus limosus [4], Acetobacter indonesiensis
FIG. 1. Phylogenetic tree based on 16S rDNA sequences showing the taxonomic position of bacteria of the genus Pandoraea
(a) (b)
FIG. 2. Lung CT obtained before the lung transplantation (A) and 3 weeks after lung transplantation (B) showing large parenchymal cavity and
bilateral alveolar opacities.
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[5], Brevundimonas diminuta, Ochrobactrum anthropi [6], and
bacteria of the genus Pandoraea [7] (Fig. 1) suggesting that
these bacteria may be selected during therapy with colistin for
chronic colonization with P. aeruginosa. This hypothesis is
strongly supported for Pandoraea species since in all published
cases, CF patients were co-colonized with P. aeruginosa [2,8–
10]. In our report we eventually identiﬁed P. pulmonicola by a
molecular method and also we have demonstrated the
accuracy and usefulness of MALDI-TOF as a routine technique
for rapid identiﬁcation of this bacterium as previously
described [3,11]. The pathogenicity of Pandoraea species
remains controversial and there are only a few reports
concerning lung transplant patients in the literature. However,
there is evidence of lung function decline as well as patient--
to-patient transmission of these bacteria in CF patients, at least
for P. apista [8]. Whether this bacterium has contributed to
the poor outcome of the patient before and/or after BLT
remains unclear since P. aeruginosa was also repeatedly isolated
during this period and our patient eventually died of P.
aeruginosa sepsis. In our review of the literature we found only
four cases of transplantation in CF patients chronically
colonized with bacteria of the genus Pandoraea [2] including
three cases of P. apista (one case from Denmark and two cases
from the USA), and one case of P. pulmonicola from Ireland. In
the case report from Australia, one CF patient was chronically
colonized by P. sputorum and this patient was not considered
to be a suitable candidate for transplantation [2]. For the four
CF transplanted patients reviewed, the three patients previ-
ously colonized with P. apista and the patient with P.
pulmonicola survived after BLT. There is only one case of a
30-year-old man suffering from end-stage pulmonary sarcoid-
osis who died from P. pnomenusa sepsis after lung transplan-
tation, suggesting that Pandoraea species may lead to severe
infections in patients with chronic lung diseases [12]. To the
best of our knowledge, our case of a CF patient chronically
colonized with P. pulmonicola is the ﬁrst human case reported
from France. The lack of available effective antibiotics for the
treatment of such infections due to the pan-resistant pheno-
type and the possibility of transmission between patients
re-emphasizes the need to implement control strategy policies
to protect the CF community, especially contact isolation
procedures during follow-up visits and hospitalizations [8].
References
1. Coenye T, Liu L, Vandamme P, Lipuma JJ. Identiﬁcation of Pandoraea
species by 16S ribosomal DNA-based PCR assays. J Clin Microbiol 2001;
39: 4452–4455.
2. Pimentel JD, MacLeod C. Misidentiﬁcation of Pandoraea sputorum
isolated from sputum of a patient with cystic ﬁbrosis and review of
Pandoraea species infections in transplant patients. J Clin Microbiol 2008;
46: 3165–3168.
3. Seng P, Drancourt M, Gouriet F, La Scola B, Fournier PE, Rolain JM
et al. On-going revolution in bacteriology: routine identiﬁcation by
matrix-assisted laser desorption ionization time-of-ﬂight mass spec-
trometry. Clin Infect Dis 2009; 49: 543–551.
4. Bittar F, Leydier A, Bosdure E, Toro A, Boniface S, Stremler N et al.
Inquilinus limosus and cystic ﬁbrosis. Emerg Infect Dis 2008; 14: 993–995.
5. Bittar F, Reynaud-Gaubert M, Thomas P, Boniface S, Raoult D, Rolain
JM. Acetobacter indonesiensis pneumonia after lung transplant. Emerg
Infect Dis 2008; 14: 997–998.
6. Menuet M, Bittar F, Stremler N, Dubus JC, Sarles J, Raoult D et al. First
isolation of two colistin-resistant emerging pathogens, Brevundimonas
diminuta and Ochrobactrum anthropi, in a woman with cystic ﬁbrosis: a
case report. J Med Case Rep 2008; 2: 373.
7. Bittar F, Rolain JM. Detection and accurate identiﬁcation of new or
emerging bacteria in cystic ﬁbrosis patients. Clin Microbiol Infect 2010;
16: 809–820.
8. Jorgensen IM, Johansen HK, Frederiksen B, Pressler T, Hansen A,
Vandamme P et al. Epidemic spread of Pandoraea apista, a new
pathogen causing severe lung disease in cystic ﬁbrosis patients. Pediatr
Pulmonol 2003; 36: 439–446.
9. Atkinson RM, Lipuma JJ, Rosenbluth DB, Dunne WM Jr. Chronic
colonization with Pandoraea apista in cystic ﬁbrosis patients determined
by repetitive-element-sequence PCR. J Clin Microbiol 2006; 44: 833–836.
10. Perez dA-B, Buendia-Moreno B, Giron-Moreno RM, Lopez-Brea M.
Pandoraea pulmonicola isolation in patients with cystic ﬁbrosis. Enferm
Infecc Microbiol Clin 2006; 24: 473–474.
11. Degand N, Carbonnelle E, Dauphin B, Beretti JL, Le BM, Ser-
met-Gaudelus I et al. Matrix-assisted laser desorption ionization-time
of ﬂight mass spectrometry for identiﬁcation of nonfermenting
gram-negative bacilli isolated from cystic ﬁbrosis patients. J Clin
Microbiol 2008; 46: 3361–3367.
12. Stryjewski ME, Lipuma JJ, Messier RH Jr, Reller LB, Alexander BD.
Sepsis, multiple organ failure, and death due to Pandoraea pnomenusa
infection after lung transplantation. J Clin Microbiol 2003; 41: 2255–
2257.
ª 2013 The Authors. New Microbes and New Infections published by John Wiley & Sons Ltd on behalf of the European Society of Clinical Microbiology and Infectious Diseases, NMNI, 1, 27–29
NMNI S. Kokcha et al. Pandoraea pulmonicola and Cystic Fibrosis 29
Open access under CC BY-NC-ND license.
